search

Pasithea Therapeutics Corp (KTTA)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Sep 14, 2026

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics (Nasdaq: KTTA) will present initial clinical data from its Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference. The data, marking the first public disclosure from Part A of the trial, will be shared through both an oral presentation on cutaneous neurofibromas and a poster presentation on plexiform neurofibromas. The conference is scheduled for November 12–14, 2026, in Vienna, Austria.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish